Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving antigen-antibody binding – specific binding protein...
Reexamination Certificate
1999-09-01
2004-08-17
Chen, Shin-Lin (Department: 1632)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving antigen-antibody binding, specific binding protein...
C435S007100, C435S375000, C530S350000, C530S412000, C530S417000, C424S192100
Reexamination Certificate
active
06777196
ABSTRACT:
BACKGROUND OF THE INVENTION
INTRODUCTION
1. Technical Field
The present invention relates to a Neurturin (“NTN”) receptor designated NTNR&agr; (also referred to as GFR&agr;2), and provides for NTNR&agr;-encoding nucleic acid and amino acid sequences. In particular, the invention relates to native sequence NTNR&agr;, NTNR&agr; variants, soluble NTNR&agr; variants including NTNR&agr; extracellular domain, chimeric NTNR&agr;, and antibodies which bind to the NTNR&agr; (including agonist and neutralizing antibodies), as well as various uses for these molecules. It also relates to assay systems for detecting ligands to NTNR&agr;, systems for studying the physiological role of NTN, diagnostic techniques for identifying NTN-related conditions, therapeutic techniques for the treatment of NTN-related and NTNR&agr;-related conditions, and methods for identifying molecules homologous to NTNR&agr;.
2. Background
Neurotrophic factors such as insulin-like growth factors, nerve growth factor, brain-derived neurotrophic factor, neurotrophin-3, -4/5 and -6, ciliary neurotrophic factor, GDNF, and neurturin have been proposed as potential means for enhancing specific neuronal cell survival, for example, as a treatment for neurodegenerative diseases such as amyotrophic lateral sclerosis, Alzheimer's disease, stroke, epilepsy, Huntington's disease, Parkinson's disease, and peripheral neuropathy. It would be desirable to provide additional therapy for this purpose. Protein neurotrophic factors, or neurotrophins, which influence growth and development of the vertebrate nervous system, are believed to play an important role in promoting the differentiation, survival, and function of diverse groups of neurons in the brain and periphery. Neurotrophic factors are believed to have important signaling functions in neural tissues, based in part upon the precedent established with nerve growth factor (NGF). NGF supports the survival of sympathetic, sensory, and basal forebrain neurons both in vitro and in vivo. Administration of exogenous NGF rescues neurons from cell death during development. Conversely, removal or sequestration of endogenous NGF by administration of anti-NGF antibodies promotes such cell death (Heumann,
J. Exp. Biol.,
132:133-150 (1987); Hefti,
J. Neurosci.,
6:2155-2162 (1986); Thoenen et al.,
Annu. Rev. Physiol.,
60:284-335 (1980)).
Additional neurotrophic factors related to NGF have since been identified. These include brain-derived neurotrophic factor (BDNF) (Leibrock, et al.,
Nature,
341:149-152 (1989)), neurotrophin-3 (NT-3) (Kaisho, et al.,
FEBS Lett.,
266:187 (1990); Maisonpierre, et al.,
Science,
247:1446 (1990); Rosenthal, et al.,
Neuron,
4:767 (1990)), and neurotrophin 4/5 (NT4/5) (Berkmeier, et al.,
Neuron,
7:857-866 (1991)).
Neurotrophins, similar to other polypeptide growth factors, affect their target cells through interactions with cell surface receptors. According to current understanding, two kinds of transmembrane glycoproteins act as receptors for the known neurotrophins. Equilibrium binding studies have shown that neurotrophin-responsive neuronal cells possess a common low molecular weight (65,000 -80,000 Daltons), a low affinity receptor typically referred to as p75
LNGFR
or p75, and a high molecular weight (130,000-150,000 Dalton) receptor. The high affinity receptors are members of the trk family of receptor tyrosine kinases.
Receptor tyrosine kinases are known to serve as receptors for a variety of protein factors that promote cellular proliferation, differentiation, and survival. In addition to the trk receptors, examples of other receptor tyrosine kinases include the receptors for epidermal growth factor (EGF), fibroblast growth factor (FGF), and platelet-derived growth factor (PDGF). Typically, these receptors span the cell membrane, with one portion of the receptor being intracellular and in contact with the cytoplasm, and another portion of the receptor being extracellular. Binding of a ligand to the extracellular portion of the receptor induces tyrosine kinase activity in the intracellular portion of the receptor, with ensuing phosphorylation of various intracellular proteins involved in cellular signaling pathways.
Glial cell line-derived neurotrophic factor (“GDNF”) and Neurturin (“NTN”) are two, recently identified, structurally related, potent survival factors for sympathetic sensory and central nervous system neurons (Lin et al.
Science
260:1130-1132 (1993); Henderson et al.
Science
266:1062-1064 (1994); Buj-Bello et al.,
Neuron
15:821-828 (1995); Kotzbauer et al.
Nature
384:467-470 (1996)). Recently, GDNF was shown to mediate its actions through a multi-component receptor system composed of a ligand binding glycosyl-phosphatidyl inositol (GPI) linked protein (designated GDNFR&agr;; also designated GFR-alpha-1) and the transmembrane receptor tyrosine kinase Ret (Treanor et al.
Nature
382:80-83 (1996); Jing et al.
Cell
85:1113-1124 (1996); Trupp et al.
Nature
381:785-789 (1996); Durbec et al.
Nature
381:789-793 (1996)). The mechanism by which the NTN signal is transmitted has not been elucidated.
Aberrant expression of receptor tyrosine kinases (“RTK”) correlates with transforming ability. For example, carcinomas of the liver, lung, breast and colon show elevated expression of Eph RTK. Unlike many other tyrosine kinases, this elevated expression can occur in the absence of gene amplification or rearrangement. Moreover, Hek, a human RTK, has been identified as a leukemia-specific marker present on the surface of a pre-B cell leukemia cell line. As with Eph, Hek also was overexpressed in the absence of gene amplification or rearrangements in, for example, hemopoietic tumors and lymphoid tumor cell lines. Over-expression of Myk-1 (a murine homolog of human Htk (Bennett et al.,
J. Biol. Chem.,
269(19):14211-8 (1994)) was found in the undifferentiated and invasive mammary tumors of transgenic mice expressing the Ha-ras oncogene. (Andres et al.,
Oncogene,
9(5):1461-7 (1994) and Andres et al.,
Oncogene,
9(8):2431 (1994)). Ret, the product of the c-ret proto-oncogene, is a member of the receptor tyrosine kinase superfamily.
In addition to their roles in carcinogenesis, a number of transmembrane tyrosine kinases have been reported to play key roles during development. Some receptor tyrosine kinases are developmentally regulated and predominantly expressed in embryonic tissues. Examples include Cek1, which belongs to the FGF subclass, and the Cek4 and Cek5 tyrosine kinases (Pasquale et al.,
Proc. Natl. Acad. Sci., USA,
86:5449-5453 (1989); Sajjadi et al.,
New Biol.,
3(8):769-78 (1991); and Pasquale,
Cell Regulation,
2:523-534 (1991)). Eph family members are expressed in many different adult tissues, with several family members expressed in the nervous system or specifically in neurons (Maisonpierre et al.,
Oncogene,
8:3277-3288 (1993); Lai et al.,
Neuron,
6:691-704 (1991)).
The aberrant expression or uncontrolled regulation of any one of these receptor tyrosine kinases can result in different malignancies and pathological disorders. Therefore, there exists a need to identify means to regulate, control and manipulate receptor tyrosine kinases (“RTK”) and their associated ligands or GPI-inked receptors, in order to provide new and additional means for the diagnosis and therapy of receptor tyrosine kinase pathway-related disorders and cellular processes. The present application provides the clinician and researcher with such means by providing new molecules that are specific for interacting with certain RTK receptors. These compounds and their methods of use, as provided herein, allow exquisite therapeutic control and specificity. Accordingly, it is an object of the present invention to provide an improved therapy for the prevention and/or treatment of neurological conditions and other conditions in which certain neurotrophic signaling pathways play a role.
These and other objects of the invention will be apparent to the ordinarily skilled artisan upon consideration of the specification as a whole.
SUMMAR
Hynes Mary A.
Klein Robert D.
Rosenthal Arnon
Chen Shin-Lin
Genentech Inc.
LandOfFree
Neurturin receptor does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Neurturin receptor, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Neurturin receptor will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3286278